The suprachoroidal pathway: a new drug delivery route to the back of the eye

Uma Do J.P. Rai; Simon A. Young; Thilini R. Thrimawithana; Hamdy Abdelkader; Adam W.G. Alani; Barbara Pierscionek; Raid G. Alany

doi:10.1016/j.drudis.2014.10.010

The suprachoroidal pathway: a new drug delivery route to the back of the eye

Uma Do J.P. Rai
, Simon A. Young
, Thilini R. Thrimawithana
, Hamdy Abdelkader
, Adam W.G. Alani
, Barbara Pierscionek
, Raid G. Alany

Research output: Contribution to journal › Article › peer-review

Abstract

The development of safe and convenient drug delivery strategies for treatment of posterior segment eye diseases is challenging. Although intravitreal injection has wide acceptance amongst clinicians, its use is associated with serious side-effects. Recently, the suprachoroidal space (SCS) has attracted the attention of ophthalmologists and pharmaceutical formulators as a potential site for drug administration and delivery to the posterior segment of the eye. This review highlights the major constraints of drug delivery to the posterior eye segment, key anatomical and physiological features of the SCS and drug delivery applications of this route with emphasis on microneedles along with future perspectives.

Original language	English
Pages (from-to)	491-495
Journal	Drug Discovery Today
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/j.drudis.2014.10.010
Publication status	Published - Apr 2015

Keywords

drug injection
suprachoroidal space
treatment
drug delivery
posterior segment eye disease
Pharmacy

Access to Document

10.1016/j.drudis.2014.10.010

http://dx.doi.org/10.1016/j.drudis.2014.10.010

Cite this

@article{23b11abe99334b9fbc9904d499998e05,

title = "The suprachoroidal pathway: a new drug delivery route to the back of the eye",

abstract = "The development of safe and convenient drug delivery strategies for treatment of posterior segment eye diseases is challenging. Although intravitreal injection has wide acceptance amongst clinicians, its use is associated with serious side-effects. Recently, the suprachoroidal space (SCS) has attracted the attention of ophthalmologists and pharmaceutical formulators as a potential site for drug administration and delivery to the posterior segment of the eye. This review highlights the major constraints of drug delivery to the posterior eye segment, key anatomical and physiological features of the SCS and drug delivery applications of this route with emphasis on microneedles along with future perspectives.",

keywords = "drug injection, suprachoroidal space, treatment, drug delivery, posterior segment eye disease, Pharmacy",

author = "Rai, \{Uma Do J.P.\} and Young, \{Simon A.\} and Thrimawithana, \{Thilini R.\} and Hamdy Abdelkader and Alani, \{Adam W.G.\} and Barbara Pierscionek and Alany, \{Raid G.\}",

year = "2015",

month = apr,

doi = "10.1016/j.drudis.2014.10.010",

language = "English",

volume = "20",

pages = "491--495",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - The suprachoroidal pathway

T2 - a new drug delivery route to the back of the eye

AU - Rai, Uma Do J.P.

AU - Young, Simon A.

AU - Thrimawithana, Thilini R.

AU - Abdelkader, Hamdy

AU - Alani, Adam W.G.

AU - Pierscionek, Barbara

AU - Alany, Raid G.

PY - 2015/4

Y1 - 2015/4

N2 - The development of safe and convenient drug delivery strategies for treatment of posterior segment eye diseases is challenging. Although intravitreal injection has wide acceptance amongst clinicians, its use is associated with serious side-effects. Recently, the suprachoroidal space (SCS) has attracted the attention of ophthalmologists and pharmaceutical formulators as a potential site for drug administration and delivery to the posterior segment of the eye. This review highlights the major constraints of drug delivery to the posterior eye segment, key anatomical and physiological features of the SCS and drug delivery applications of this route with emphasis on microneedles along with future perspectives.

AB - The development of safe and convenient drug delivery strategies for treatment of posterior segment eye diseases is challenging. Although intravitreal injection has wide acceptance amongst clinicians, its use is associated with serious side-effects. Recently, the suprachoroidal space (SCS) has attracted the attention of ophthalmologists and pharmaceutical formulators as a potential site for drug administration and delivery to the posterior segment of the eye. This review highlights the major constraints of drug delivery to the posterior eye segment, key anatomical and physiological features of the SCS and drug delivery applications of this route with emphasis on microneedles along with future perspectives.

KW - drug injection

KW - suprachoroidal space

KW - treatment

KW - drug delivery

KW - posterior segment eye disease

KW - Pharmacy

UR - http://www.ncbi.nlm.nih.gov/pubmed/25448755

U2 - 10.1016/j.drudis.2014.10.010

DO - 10.1016/j.drudis.2014.10.010

M3 - Article

C2 - 25448755

SN - 1359-6446

VL - 20

SP - 491

EP - 495

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 4

ER -

The suprachoroidal pathway: a new drug delivery route to the back of the eye

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this